An Overview of Drug Resistance in Protozoal Diseases
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Protozoan diseases continue to be a worldwide social and economic health problem. Increased drug resistance, emerging cross resistance, and lack of new drugs with novel mechanisms of action significantly reduce the effectiveness of current antiprotozoal therapies. While drug resistance associated to anti-infective agents is a reality, society seems to remain unaware of its proportions and consequences. Parasites usually develops ingenious and innovative mechanisms to achieve drug resistance, which requires more research and investment to fight it. In this review, drug resistance developed by protozoan parasites Plasmodium, Leishmania, and Trypanosoma will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K.-J., Coppes, R. P., Engedal, N., Mari, M., & Reggiori, F. (2018) · Autophagy · doi:10.1080/15548627.2018.1474314 · Cited by 2,122 · cited 1×
“CQ and related 4-aminoquinolines act through the inhibition of hemozoin formation in the digestive vacuole, during ring and trophozoite stages [22].”
BackgroundBurza, S., Croft, S. L., & Boelaert, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31204-2 · Cited by 1,913
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663 · cited 1×
“The incorrect use of antimonials by a majority of patients expose the parasites to drug pressure, leading to the development of tolerance, and eventually resistance, of the parasite to Sb(V) [72].”
Torres-Guerrero, E., Quintanilla-Cedillo, M. R., Ruiz-Esmenjaud, J., & Arenas, R. (2017) · F1000Research · doi:10.12688/f1000research.11120.1 · Cited by 1,066
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962 · cited 4×
“In eukaryotic Leishmania parasite the knowledge about the mechanisms of resistance is narrow, but they should involve a decreased drug uptake [73,121,122].”
BackgroundInfluentialMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Büscher, P., Cecchi, G., Jamonneau, V., & Priotto, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31510-6 · Cited by 693
Tjitra, E., Anstey, N. M., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Lampah, D. A., & Price, R. N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050128 · Cited by 611
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes
Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M., & Cheeseman, I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711014105 · Cited by 457 · cited 1×
“The one-electron reduction of the nitro group can also generate free radicals that can induce oxidative damage, leading to death of the parasite [143,144].”
BackgroundEnteric Protozoa in the Developed World: a Public Health Perspective
Fletcher, S. M., Stark, D., Harkness, J., & Ellis, J. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05038-11 · Cited by 434 · cited 1×
“) are severe diseases that threaten human lives of nearly onesixth of the world population [1].”
BackgroundLeishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348 · cited 5×
“The major limitations of MT are the teratogenicity nature, the potential of resistance due to its long half-life (∼one week) and prolonged presence of sub-therapeutic concentrations, and its elevated cost [79].”
BackgroundInfluentialVeiga, M. I., Dhingra, S. K., Henrich, P. P., Straimer, J., Gnädig, N., Uhlemann, A.-C., Martin, R. E., Lehane, A. M., & Fidock, D. A. (2016) · Nature Communications · doi:10.1038/ncomms11553 · Cited by 335 · cited 1×
“Polymorphism, amplification, and variation in mRNA expression level of the Pfmdr1 gene have been involved in resistance to various antimalarials and emergence of multidrug resistance parasites [29].”
BackgroundMechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-11 · Cited by 324 · cited 18×
“These cumulative effects of a changed membrane profile, involving MDR1 and the tryparedoxin cascade may be responsible for making the Leishmania parasites resistant to AMB [96,98].”
BackgroundInfluentialAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network
Cui, L., Mharakurwa, S., Ndiaye, D., Rathod, P. K., & Rosenthal, P. J. (2015) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.15-0007 · Cited by 305 · cited 6×
“The presence of this mutation has important policy implications for the eventual general deployment of the spiroindolone KAE609 (Cipargamin), which is currently undergoing stage 2 clinical trials and initiate parenteral administration in humans in 2019 [26,36].”
BackgroundInfluentialDrug‐resistant malaria: Molecular mechanisms and implications for public health
Petersen, I., Eastman, R., & Lanzer, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.042 · Cited by 289 · cited 1×
“Due to that, the DNNND repeat number can only be a valid marker for quinine resistance in some genetic backgrounds, but not for all [34,35].”
BackgroundMalarial hemozoin: From target to tool
Coronado, L. M., Nadovich, C. T., & Spadafora, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.009 · Cited by 289 · cited 1×
“Dicationic CQ interferes with the parasite detoxification process by inhibiting the transformation of heme (toxic to parasite) into hemozoin (non-toxic to parasite) [23,24].”
BackgroundThe development of drugs for treatment of sleeping sickness: a historical review
Steverding, D. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-15 · Cited by 274
Drug resistance in leishmaniasis
Chakravarty, J., & Sundar, S. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62887 · Cited by 270
Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites
Hall, B. S., Bot, C., & Wilkinson, S. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.230847 · Cited by 262
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future
Bray, P. G., Barrett, M. P., Ward, S. A., & de Koning, H. P. (2003) · Trends in Parasitology · doi:10.1016/s1471-4922(03)00069-2 · Cited by 261 · cited 1×
“However, the maximum velocity of uptake is substantially higher in amastigotes than in promastigotes [85,86].”
BackgroundRoss, L. S., Dhingra, S. K., Mok, S., Yeo, T., Wicht, K. J., Kümpornsin, K., Takala-Harrison, S., Witkowski, B., Fairhurst, R. M., Ariey, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05652-0 · Cited by 256 · cited 3×
“falciparum multidrug resistance protein 1 (PfMDR1) [24].”
BackgroundMechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes
Mbongo, N., Loiseau, P. M., Billion, M. A., & Robert-Géro, M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.352 · Cited by 240 · cited 18×
“These cumulative effects of a changed membrane profile, involving MDR1 and the tryparedoxin cascade may be responsible for making the Leishmania parasites resistant to AMB [96,98].”
BackgroundInfluentialA current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis
Babokhov, P., Sanyaolu, A. O., Oyibo, W. A., Fagbenro-Beyioku, A. F., & Iriemenam, N. C. (2013) · Pathogens and Global Health · doi:10.1179/2047773213y.0000000105 · Cited by 236 · cited 2×
“In contrast, suramin inhibits the activity of pentamidine [134].”
BackgroundEflornithine for the treatment of human African trypanosomiasis
Burri, C., & Brun, R. (2003) · Parasitology Research · doi:10.1007/s00436-002-0766-5 · Cited by 227 · cited 1×
“rhodesiense to DFMO has been ascribed to the higher ODC turnover in this parasite [139].”
BackgroundDrug Resistance in Visceral Leishmaniasis
Maltezou, H. C. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/617521 · Cited by 218 · cited 8×
“LMDR1/ABCB4, a P-glycoprotein-like transporter included in the Leishmania ABC transporters, was the first molecule shown to be involved in experimental MT resistance.”
BackgroundInfluentialAntimalarial drug resistance: An overview
Parija, S., & Antony, H. (2016) · Tropical Parasitology · doi:10.4103/2229-5070.175081 · Cited by 215
Antimalarial pharmacology and therapeutics of atovaquone
Nixon, G. L., Moss, D. M., Shone, A. E., Lalloo, D. G., Fisher, N., O'Neill, P. M., Ward, S. A., & Biagini, G. A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks504 · Cited by 208 · cited 5×
“The underlying reason for this phenomenon may be partially explained by pharmacodynamic/pharmacokinetic properties of atovaquone, combined with the effect of an increased mutation rate of mitochondrially encoded genes such as cytochrome b compared with nuclear encoded genes [56,59].”
BackgroundInfluentialParomomycin: Uptake and resistance in Leishmania donovani
Jhingran, A., Chawla, B., Saxena, S. K., Barrett, M. P., & Madhubala, R. (2008) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2008.12.007 · Cited by 197
Basselin, M., Denise, H., Coombs, G. H., & Barrett, M. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3731-3738.2002 · Cited by 195 · cited 2×
“However, the maximum velocity of uptake is substantially higher in amastigotes than in promastigotes [85,86].”
BackgroundA thiol probe for measuring unfolded protein load and proteostasis in cells
Chen, M. Z., Moily, N. S., Bridgford, J. L., Wood, R. J., Radwan, M., Smith, T. A., Song, Z., Tang, B. Z., Tilley, L., Xu, X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00203-5 · Cited by 189 · cited 1×
“These reactive intermediates are proposed to alkylate proteins and form adducts with essential parasite macromolecules that result in the rapid death of the parasite [44,46,47].”
BackgroundResistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
Nsanzabana, C. (2019) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4010026 · Cited by 188
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
Vincent, I. M., Creek, D., Watson, D. G., Kamleh, M. A., Woods, D. J., Wong, P. E., Burchmore, R. J. S., & Barrett, M. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001204 · Cited by 184 · cited 2×
“The risk of clinical resistance to DMFO is, unfortunately, a reality due to their continued administration alone or in combination with nifurtimox [140].”
BackgroundApoptotic Death in Leishmania donovani Promastigotes in Response to Respiratory Chain Inhibition
Mehta, A., & Shaha, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309341200 · Cited by 180
The interplay between drug resistance and fitness in malaria parasites
Rosenthal, P. J. (2013) · Molecular Microbiology · doi:10.1111/mmi.12349 · Cited by 176 · cited 2×
“In addition, intensification of antimalarial drug resistance can also be ascribed to cross resistance between drugs of the same chemical family or sharing similar modes of action [19].”
BackgroundDefining the Timing of Action of Antimalarial Drugs against Plasmodium falciparum
Wilson, D. W., Langer, C., Goodman, C. D., McFadden, G. I., & Beeson, J. G. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01881-12 · Cited by 175 · cited 1×
“falciparum malaria, the most important drugs are developed to target either the food vacuole of ring-stage and trophozoites of blood-stage malaria or the enzymes involved in the trophozoite folic acid biosynthesis pathway [14].”
BackgroundLeishmaniasis: A Review on Parasite, Vector and Reservoir Host
Alemayehu, B., & Alemayehu, M. (2017) · Health Science Journal · doi:10.21767/1791-809x.1000519 · Cited by 175 · cited 1×
“The macrophage lyses and the multiplication cycle continues when other hosts’ phagocytes are infected [64].”
BackgroundThe evolution of transmission mode
Antonovics, J., Wilson, A. J., Forbes, M. R., Hauffe, H. C., Kallio, E. R. K., Leggett, H. C., Longdon, B., Okamura, B., Sait, S. M., & Webster, J. P. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0083 · Cited by 173
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Srivastava, S., Mishra, J., Gupta, A. K., Singh, A., Shankar, P., & Singh, S. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-1969-z · Cited by 167 · cited 5×
“donovani) in the laboratory allowed phenotypic and genotypic characterization of the isolates [105].”
BackgroundInfluentialDemas, A. R., Sharma, A. I., Wong, W., Early, A. M., Redmond, S., Bopp, S., Neafsey, D. E., Volkman, S. K., Hartl, D. L., & Wirth, D. F. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812317115 · Cited by 162 · cited 1×
“This gene encodes for actinbinding protein Coronin and when this mutation was introduced into the parenteral parasites a reduction in ART susceptibility was observed [54].”
Visceral Leishmaniasis and HIV Coinfection in East Africa
Diro, E., Lynen, L., Ritmeijer, K., Boelaert, M., Hailu, A., & van Griensven, J. (2014) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002869 · Cited by 160 · cited 1×
“Additionally, the control of the disease in these countries is further compromised by the emergence of HIV-VL co-infection [67].”
BackgroundAquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes
Baker, N., Glover, L., Munday, J. C., Aguinaga Andrés, D., Barrett, M. P., de Koning, H. P., & Horn, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202885109 · Cited by 158 · cited 1×
“Aquaglyceroporin 2 (AQP2), a member of a family of surface channel proteins involved in the passive transport of water and small non-charged solutes across cell membranes, is the transporter responsible for resistance to high concentrations of pentamidine and melarsoprol in trypanosomes [89].”
BackgroundClinical and Neuropathogenetic Aspects of Human African Trypanosomiasis
Kennedy, P. G. E., & Rodgers, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00039 · Cited by 158 · cited 1×
“The interaction between immune response of the host and antigenic variation of the parasite results in an irregular parasitaemia, reflected by irregular fevers [123,126].”
BackgroundAntimalarial activity of primaquine operates via a two-step biochemical relay
Camarda, G., Jirawatcharadech, P., Priestley, R. S., Saif, A., March, S., Wong, M. H. L., Leung, S. C., Miller, A. B., Baker, D. A., Alano, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11239-0 · Cited by 153 · cited 2×
“Sci. 2019, 20, 5748 4 of 33 Atovaquone Prophylaxis of malaria and treatment of uncomplicated malaria in travellers outside endemic areas in combination with proguanil Inhibits the respiratory function of parasite Pfcytb mutation Artemisinin Artesunate Artemether Multidrug-resistant Pf infection Combination with other…”
BackgroundChawla, B., Jhingran, A., Panigrahi, A. K., Stuart, K. D., & Madhubala, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026660 · Cited by 149
Qinghaosu (artemisinin): Chemistry and pharmacology
Li, Y. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.104 · Cited by 145 · cited 1×
“These reactive intermediates are proposed to alkylate proteins and form adducts with essential parasite macromolecules that result in the rapid death of the parasite [44,46,47].”
BackgroundArtemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia
Mukherjee, A., Bopp, S. E. R., Magistrado-Coxen, P., Wong, W., Daniels, R. F., Demas, A. R., Schaffner, S. F., Amaratunga, C., Lim, P., Dhorda, M., et al. (2017) · Malaria Journal · doi:10.1186/s12936-017-1845-5 · Cited by 133 · cited 1×
“Mutations in kelch13 gene are usually considered as a genetic marker for artemisinin resistance [20,30] but some other polymorphisms have also been described as responsible for increased parasite clearance time [52].”
BackgroundPinto-Martínez, A., Rodríguez-Durán, J., Serrano-Martín, X., Hernández-Rodríguez, V., & Benaím, G. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01614-17 · Cited by 128
Munday, J. C., Eze, A. A., Baker, N., Glover, L., Clucas, C., Aguinaga Andres, D., Natto, M. J., Teka, I. A., McDonald, J., Lee, R. S., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt442 · Cited by 127 · cited 1×
“Studies need to be done, but there is the possibility that AQP2 mutation can also be responsible for pentamidine resistance in Leishmania parasites [74,90,91].”
BackgroundMelarsoprol Resistance in African Trypanosomiasis
Fairlamb, A. H., & Horn, D. (2018) · Trends in Parasitology · doi:10.1016/j.pt.2018.04.002 · Cited by 125 · cited 2×
“The only drugs that can cross the blood-brain barrier and be used in the second stage of the disease are Mel B and NECT, with Mel B being the only one with clinically proved resistance, particularly in central Africa [136].”
BackgroundAspinall, T. V., Joynson, D. H. M., Guy, E. C., Hyde, J. E., & Sims, P. F. G. (2002) · The Journal of Infectious Diseases · doi:10.1086/340577 · Cited by 123
Thriemer, K., Hong, N. V., Rosanas‐Urgell, A., Phuc, B. Q., Ha, D. M., Pockele, E., Guetens, P., Van, N. V., Duong, T. T., Amambua‐Ngwa, A., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02746-14 · Cited by 106 · cited 2×
“Sci. 2019, 20, 29 of 33 Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam.”
BackgroundRoles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani
Mukherjee, A., Padmanabhan, P. K., Sahani, M. H., Barrett, M. P., & Madhubala, R. (2005) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2005.08.016 · Cited by 103
Ismail, H. M., Barton, V., Phanchana, M., Charoensutthivarakul, S., Biagini, G. A., Ward, S. A., & O’Neill, P. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201512062 · Cited by 101
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Bakshi, R. P., Tatham, L. M., Savage, A. C., Tripathi, A. K., Mlambo, G., Ippolito, M. M., Nenortas, E., Rannard, S. P., Owen, A., & Shapiro, T. A. (2018) · Nature Communications · doi:10.1038/s41467-017-02603-z · Cited by 93
Munday, J. C., Settimo, L., & de Koning, H. P. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00032 · Cited by 90
Heinberg, A. R., & Kirkman, L. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12662 · Cited by 87
Differential Effects of Paromomycin on Ribosomes ofLeishmania mexicanaand Mammalian Cells
Fernández, M. M., Malchiodi, E. L., & Algranati, I. D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00506-10 · Cited by 86
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Wiwanitkit, V. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30139 · Cited by 85 · cited 1×
“PMM is usually well tolerated, can be administrated by oral route or by intramuscular injection, and secondary effects are rare [114].”
BackgroundHirve, S. S., Boelaert, M., Matlashewski, G., Mondal, D., Arana, B. A., Kroeger, A., & Olliaro, P. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004896 · Cited by 84 · cited 2×
“(2) Post-kala-azar dermal leishmaniasis (PKDL), which usually appears six months to one year after apparent cure of VL. (3) Cutaneous leishmaniasis (CL), the most common, causes skin lesions, mainly ulcers on exposed parts of the body, leaving lifelong scars.”
BackgroundSiciliano, G., & Alano, P. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00391 · Cited by 84 · cited 1×
“falciparum infection, the ability of parasites to sequester in the microvasculature of several organs, including the brain, is a major cause of disease severity, and of a fatal outcome [10,11].”
BackgroundArtemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
Konstat-Korzenny, E., Ascencio-Aragón, J. A., Niezen, S., & Vázquez-López, R. (2018) · Medical Sciences · doi:10.3390/medsci6010019 · Cited by 82
Pachioni-Vasconcelos, J. A., Magalhães, J. G., Lima, E. J. C., Bueno, L., Barbosa, J. F., de Sá, M. M., & Rangel‐Yagui, C. D. O. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3cw23 · Cited by 80 · cited 1×
“MT inhibits the biosynthesis of phosphatidylcholine, thus affecting phospholipid biosynthesis [79,103].”
BackgroundShaw, C. D., Lonchamp, J., Downing, T., Imamura, H., Freeman, T. M., Cotton, J. A., Sanders, M. J., Blackburn, G. J., Dujardin, J., Rijal, S., et al. (2015) · Molecular Microbiology · doi:10.1111/mmi.13291 · Cited by 76
Turcano, L., Torrente, E., Missineo, A., Andreini, M., GRAMICCIA, M., Muccio, T. D., Genovese, I., Fiorillo, A., Harper, S., Bresciani, A., et al. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006969 · Cited by 76 · cited 1×
“In contrast to mammals, which use glutathione (GSH) as the fundamental key for redox defenses, trypanosomatid parasites rely on trypanothione as the main detoxifying system against oxidative damage [69].”
BackgroundDesign and Evaluation of Primaquine-Artemisinin Hybrids as a Multistage Antimalarial Strategy
Capela, R., Cabal, G. G., Rosenthal, P. J., Gut, J., Mota, M. M., Moreira, R., Lopes, F., & Prudêncio, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05133-11 · Cited by 75
Self-citationInsights into antitrypanosomal drug mode-of-action from cytology-based profiling
Thomas, J. A., Baker, N., Hutchinson, S., Dominicus, C. S., Trenaman, A., Glover, L., Alsford, S., & Horn, D. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006980 · Cited by 74 · cited 5×
“Pentamidine acts as a DNA-binding-drug, provoking the collapse of the parasite mitochondrial membrane potential, and the induction of kinetoplast DNA destruction [129,131,132].”
BackgroundInfluentialPountain, A. W., Weidt, S. K., Regnault, C., Bates, P. A., Donachie, A. M., Dickens, N. J., & Barrett, M. P. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007052 · Cited by 72 · cited 1×
“Genetic changes in multiple AMB-resistant Leishmania lines were also observed in two sterol biosynthesis enzymes: Sterol C24-methyltransferase (SMT), which introduces the C24-methyl group within the ergosterol side chain, and sterol C5-desaturase (SC5D) which is required for generation of sterol 5(6)-7(8) double bond…”
BackgroundNovel Mutations in K13 Propeller Gene of Artemisinin-ResistantPlasmodium falciparum
Isozumi, R., Uemura, H., Kimata, I., Ichinose, Y., Logedi, J., Omar, A. H., & Kaneko, A. (2015) · Emerging infectious diseases · doi:10.3201/eid2103.140898 · Cited by 72
Heidari‐Kharaji, M., Taheri, T., Doroud, D., Habibzadeh, S., Badirzadeh, A., & Rafati, S. (2016) · Parasite Immunology · doi:10.1111/pim.12340 · Cited by 71
Bhandari, V., Sundar, S., Dujardin, J., & Salotra, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01574-13 · Cited by 70 · cited 1×
“In eukaryotic Leishmania parasite the knowledge about the mechanisms of resistance is narrow, but they should involve a decreased drug uptake [73,121,122].”
BackgroundThe Long Wait for a New Drug for Human African Trypanosomiasis
Baker, C. H., & Welburn, S. C. (2018) · Trends in Parasitology · doi:10.1016/j.pt.2018.08.006 · Cited by 66 · cited 1×
“Pentamidine acts as a DNA-binding-drug, provoking the collapse of the parasite mitochondrial membrane potential, and the induction of kinetoplast DNA destruction [129,131,132].”
BackgroundCottrell, G., Musset, L., Hubert, V., Bras, J. L., & Clain, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02550-13 · Cited by 66 · cited 1×
“The underlying reason for this phenomenon may be partially explained by pharmacodynamic/pharmacokinetic properties of atovaquone, combined with the effect of an increased mutation rate of mitochondrially encoded genes such as cytochrome b compared with nuclear encoded genes [56,59].”
BackgroundSitamaquine Overcomes ABC-Mediated Resistance to Miltefosine and Antimony inLeishmania
Pérez-Victoria, J. M., Bavchvarov, B. I., Torrecillas, I. R., Martínez‐García, M., López-Martín, C., Campillo, M., Castanys, S., & Gamarro, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00065-11 · Cited by 66 · cited 2×
“The overexpression of ABC transporters ABCB4(MDR1), ABCG4, and ABCG6 is described to be associated with an increased resistance to MT in Leishmania, leading to a reduction in intracellular accumulation due to increased efflux of the drug across the plasma membrane [70,73,111,112].”
BackgroundNanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art
Pund, S., & Joshi, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52727-9.00023-6 · Cited by 64 · cited 1×
“Amastigotes can reduce Sb(V) to Sb(III), while promastigotes cannot, rendering amastigotes more susceptible to Sb(V) [71].”
BackgroundPatel, P. P., Bharti, P. K., Bansal, D., Ali, N. A., Raman, R. K., Mohapatra, P. K., Sehgal, R., Mahanta, J., Sultan, A. A., & Singh, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-16866-5 · Cited by 61 · cited 1×
“Since the antimalarial drug resistance as monotherapy has emerged, sulfadoxine is always provided in combination with pyrimethamine, and resistance to SP have been associated with point mutation in both Pfdhfr and Pfdhps gene [20,28,40,41].”
BackgroundBarrett, M. P. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006925 · Cited by 57
Graf, F. E., Baker, N., Munday, J. C., de Koning, H. P., Horn, D., & Mäser, P. (2015) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2015.04.002 · Cited by 56
Kavishe, R. A., van den Heuvel, J. J. M. W., van de Vegte‐Bolmer, M., et al. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-205 · Cited by 55 · cited 1×
“falciparum multidrug resistance-associated protein (PfMRP) is a member of the ABC transporter superfamily, localized principally in the parasite plasma membrane [31].”
BackgroundGenetic dissection of drug resistance in trypanosomes
Alsford, S., Kelly, J. M., Baker, N., & Horn, D. (2013) · Parasitology · doi:10.1017/s003118201300022x · Cited by 54
Breglio, K. F., Amato, R., Eastman, R. T., Lim, P., Sá, J. M., Guha, R., Ganesan, S., Dorward, D. W., Klumpp-Thomas, C. A., McKnight, C. G., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2532-x · Cited by 51 · cited 1×
“One possible explanation is that this mutation can provide additional resistance against ARTs promoting a more efficient acquisition of nutrients through an autophagy-like pathway [53].”
BackgroundRodrigues, T., Lopes, F., & Moreira, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790820660 · Cited by 51 · cited 1×
“Cytochrome bc1 is predicted to have 10 putative helical transmembrane domains spanning the mitochondrial inner membrane of the parasite [20,60].”
BackgroundSelf-citationIn vitro Susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis
Prajapati, V. K., Sharma, S., Rai, M., Ostyn, B., Salotra, P., Vanaerschot, M., Dujardin, J., & Sundar, S. (2013) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.13-0096 · Cited by 49 · cited 1×
“Parasites with reduced susceptibility towards MT have been reported in the Indian subcontinent [109].”
BackgroundPérez‐Cabezas, B., Cecílio, P., Gaspar, T. B., Gärtner, F., Vasconcellos, R., & Cordeiro‐da‐Silva, A. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00030 · Cited by 49 · cited 1×
“This disease is endemic in at least 98 countries and approximately one million new cases and 26 to 65 thousand deaths occur annually [61,62].”
Background(Post-) Genomic approaches to tackle drug resistance in Leishmania
Berg, M., Mannaert, A., Vanaerschot, M., der Auwera, G. V., & Dujardin, J. (2013) · Parasitology · doi:10.1017/s0031182013000140 · Cited by 47 · cited 3×
“To avoid these drawbacks, a lipid-associated formulation, liposomal AMB (LAMB), have been developed with reduced toxicity and an extended plasma halflife, allowing the administration of a single infusion [68].”
BackgroundVoumbo-Matoumona, D. F., Kouna, L. C., Madamet, M., Maghendji-Nzdondo, S., Pradines, B., & Lékana-Douki, J. B. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s160164 · Cited by 45
Jeacock, L., Baker, N., Wiedemar, N., Mäser, P., & Horn, D. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006307 · Cited by 44
Xu, C., Wei, Q., Yin, K., Sun, H. Z., Li, J., Xiao, T., Kong, X., Wang, Y., Zhao, G., Zhu, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31207-w · Cited by 42 · cited 3×
“All the mutations have been reported to be associated with the clinical ART resistance [28,30,55].”
BackgroundFitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major
Turner, K. G., Vacchina, P., Robles‐Murguia, M., Wadsworth, M. N., McDowell, M. A., & Morales, M. A. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003948 · Cited by 41 · cited 1×
“Induction of in vitro resistance was performed previously in the laboratory to anticipate the emergence of resistance to MT and to characterize the resulting mutants [97,107,108].”
BackgroundBeyond immune escape: a variant surface glycoprotein causes suramin resistance in Trypanosoma brucei
Wiedemar, N., Graf, F. E., Zwyer, M., Ndomba, E., Renggli, C. K., Cal, M., Schmidt, R. S., Wenzler, T., & Mäser, P. (2017) · Molecular Microbiology · doi:10.1111/mmi.13854 · Cited by 40
Hombach, A., Bartsch, K., Smirlis, D., Rosenqvist, H., MacDonald, A., Dingli, F., Loew, D., Späth, G. F., Rachidi, N., Wiese, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41640-0 · Cited by 39
Weingärtner, A., Drobot, B., Herrmann, A., Sánchez‐Cañete, M. P., Gamarro, F., Castanys, S., & Pomorski, T. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012443 · Cited by 38
Safety and benefits of interventions to increase folate status in malaria‐endemic areas
Verhoef, H., Veenemans, J., Mwangi, M. N., & Prentice, A. M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14618 · Cited by 38 · cited 1×
“The interest in this class of antifolates was fostered when it was demonstrated that they synergized with anti-DHFR [37,38].”
BackgroundVeiga, M. I., Osório, N. S., Ferreira, P. E., Franzén, O., Dahlström, S., Lum, J. K., Nosten, F. H., & Gil, J. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03337-14 · Cited by 38
Kumar, G. A., Roy, S., Jafurulla, M., Mandal, C., & Chattopadhyay, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.06.010 · Cited by 37 · cited 1×
“In that way the class of statins reverse Sb resistance [74,75].”
BackgroundKaur, P., Garg, M., Hombach, A., Clos, J., & Goyal, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-09725-w · Cited by 37 · cited 1×
“Recent studies also included HSP90 as a gene implicated in the emergence of resistance in Leishmania [77,78].”
ResultTackling resistance: emerging antimalarials and new parasite targets in the era of elimination
Mathews, E. S., & John, A. R. O. (2018) · F1000Research · doi:10.12688/f1000research.14874.1 · Cited by 35 · cited 2×
“major stumbling block in the global control of malaria [21].”
BackgroundMok, S., Liong, K.-Y., Lim, E., Huang, X.-M., Zhu, L., Preiser, P., & Bozdech, Z. (2014) · Molecular Microbiology · doi:10.1111/mmi.12505 · Cited by 34
Capela, R., Magalhães, J., Miranda, D., Machado, M., Sanches‐Vaz, M., Albuquerque, I. S., Sharma, M., Gut, J., Rosenthal, P. J., Frade, R. F. M., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.048 · Cited by 34
Self-citationNew Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites
Garcia-Salcedo, J. A., Unciti-Broceta, J. D., Valverde-Pozo, J., & Soriano, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00351 · Cited by 33 · cited 6×
“In that way the class of statins reverse Sb resistance [74,75].”
BackgroundInfluentialDrugs and Drug Resistance in African and American Trypanosomiasis
Franco, J., Scarone, L., & Comini, M. A. (2018) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2018.08.003 · Cited by 30 · cited 3×
“Several transporters as the P2 adenosine/adenine may contribute to PMD uptake in trypanosomes, and after internalization by endocytosis, PMD binds to the receptor aquaglyceroporin 2 (AQP2) with affinity in the nM range [127].”
BackgroundInfluentialda Costa, K. M., Valente, R. D. C., Salustiano, E. J., Gentile, L. B., Freire‐de‐Lima, L., Mendonça‐Previato, L., & Previato, J. O. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00205 · Cited by 30
Prevalence of Protozoa Species in Drinking and Environmental Water Sources in Sudan
Shanan, S., Abd, H., Bayoumi, M., Saeed, A., & Sandström, G. (2015) · BioMed Research International · doi:10.1155/2015/345619 · Cited by 28
Cubides, J. R., Camargo-Ayala, P. A., Niño, C. H., Garzón‐Ospina, D., Ortegon, A. L. O., Ospina-Cantillo, E., Orduz-Durán, M. F., Patarroyo, M. E., & Patarroyo, M. A. (2018) · Malaria Journal · doi:10.1186/s12936-018-2286-5 · Cited by 26 · cited 1×
“Mutations in Pfmdr1, Pfcrt, Pfmrp, and Pfnhe1 genes have been fixed in several parasite populations and, since they confer drug resistance, this facilitates their dispersion [25].”
BackgroundAbugri, J., Ansah, F., Asante, K. P., Opoku, C. N., Amenga-Etego, L. A., & Awandare, G. A. (2018) · AAS Open Research · doi:10.12688/aasopenres.12825.1 · Cited by 15
Abugri, J., Ansah, F., Asante, K. P., Opoku, C. N., Amenga-Etego, L. A., & Awandare, G. A. (2018) · AAS Open Research · doi:10.12688/aasopenres.12825.2 · Cited by 14
Adaptation and Therapeutic Exploitation of the Plasma Membrane of African Trypanosomes
Quintana, J. F., Pino, R. C. D., Yamada, K., Zhang, N., & Field, M. C. (2018) · Genes · doi:10.3390/genes9070368 · Cited by 13
How to combat emerging artemisinin resistance: Lessons from “The Three Little Pigs”
Chookajorn, T. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006923 · Cited by 11 · cited 1×
“However, this delayed clearance could contribute to the rise of multidrug resistance, as parasites have gained both reduced artemisinin sensitivity and resistance against partner drugs, such as piperaquine [21,51].”
BackgroundAntifolates: Pyrimethamine, Proguanil, Sulphadoxine and Dapsone
Nzila, A. M. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0480-2_6 · Cited by 11 · cited 2×
“However, both of these drugs have been discontinued in 2008 following increasing evidence of toxicity of dapsone in the form of haemolysis in patients with G6PD deficiency [37].”
BackgroundAttenuation and Production of the Amphotericin B-Resistant Leishmania tropica Strain
Khan, I., Khan, M., Umar, M. N., & Oh, D. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.32159 · Cited by 6 · cited 1×
“The biological features of these resistant strains were compared with those of the wild-type parent strain and several mutations were observed [99].”
Result
Metadata
- Authors
- Capela, R., Moreira, R., & Lopes, F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-15
- Volume
- 20
- Issue
- 22
- Pages
- 5748
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2985586364
- Cited by
- 227
- References
- 110
- FWCI
- 19.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.